摘要
-甲胎蛋白(AFP)是一种69kDd的胎和肿瘤相关的单链糖蛋白,属于类白藜芦醇基因家族。AFP作为载体/转运分子以及生长调节剂,已被用作胎儿缺陷和癌症生长的临床生物标志物。溶血磷脂(LPL)是由附着在极性头基上的小分子量单酰基碳链(棕榈酸、油酸)组成的质膜衍生的生物活性脂质信号传导介质,它们的分子量范围250-750道尔顿。 LPL由鞘氨醇1-磷酸或溶血磷脂酸组成,主要由其胆碱,乙醇胺,丝氨酸或肌醇衍生物组成。它们只存在于脊椎动物中。这些生物活性旁分泌脂质介质普遍分布在组织中,并从涉及发育,生理和病理过程的许多不同细胞类型(血小板,巨噬细胞,单核细胞等)释放。 LPL与本文所述的四种不同类型的G-蛋白偶联受体结合,其转化多种细胞效应,其包括诸如形态发生,神经发育,血管发生和癌发生之类的活性。通过计算机模拟分析,鉴定了AFP第三结构域受体结合片段上LPL受体的潜在结合位点。可以想象,但未被证明,AFP可能不仅与LPL受体结合,而且也与LPL本身结合,因为AFP结合中长链脂肪酸。提出过去一些归于AFP的活动可能部分是由于存在结合的LPL和/或其受体。
关键词: α-甲胎蛋白,结合蛋白,细胞靶点,树突细胞,碎片,溶血磷脂,单细胞/巨噬细胞,受体
图形摘要
Current Drug Targets
Title:Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Volume: 18 Issue: 7
关键词: α-甲胎蛋白,结合蛋白,细胞靶点,树突细胞,碎片,溶血磷脂,单细胞/巨噬细胞,受体
摘要: Alpha-fetoprotein (AFP) is a 69 kD fetal- and tumor-associated single-chain glycoprotein belonging to the albuminoid gene family. AFP functions as a carrier/transport molecule as well as a growth regulator and has been utilized as a clinical biomarker for both fetal defects and cancer growth. Lysophospholipids (LPLs) are plasma membrane-derived bioactive lipid signaling mediators composed of a small molecular weight single acyl carbon chain (palmitic, oleic acid) attached to a polar headgroup; they range in molecular mass from 250-750 daltons. The LPLs consist of either sphingosine-1-phosphate or lysophosphatidic acid, and mostly their choline, ethanolamine, serine or inositol derivatives. They are present only in vertebrates. These bioactive paracrine lipid mediators are ubiquitously distributed in tissues and are released from many different cell types (platelets, macrophages, monocytes, etc.) involved in developmental, physiological, and pathological processes. The LPLs bind to four different classes of G-protein coupled receptors described herein which transduce a multiple of cell effects encompassing activities such as morphogenesis, neural development, angiogenesis, and carcinogenesis. The identification of potential binding sites of LPL receptors on the AFP third domain receptor binding fragment was derived by computer modeling analysis. It is conceivable, but not proven, that AFP might bind not only to the LPL receptors, but also to LPLs themselves since AFP binds medium and long chain fatty acids. It is proposed that some of the activities ascribed to AFP in the past might be due in part to the presence of bound LPLs and/or their receptors.
Export Options
About this article
Cite this article as:
Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450117666160201105245
DOI https://dx.doi.org/10.2174/1389450117666160201105245 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modification of Taxane A Ring via Manoeuvering of the C-11 Double Bond of 10-Deacetylbaccatin III to Get Novel Rearranged Taxoids
Letters in Organic Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer <i>via Salmonella</i> VNP20009
Anti-Cancer Agents in Medicinal Chemistry Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Editorial A New Year of Excellence
Current Molecular Medicine Insights on Melatonin as an Active Pharmacological Molecule in Cancer Prevention: What’s New?
Current Medicinal Chemistry DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Current Molecular Medicine Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Synthesis of Novel Pyridine Bearing Biologically Active Imidiazolyl, Pyrazolyl, Oxa/thiadiazolyl and Urea Derivatives as Promising Anticancer Agents
Current Organic Synthesis Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets